Ferring Favorite To Get First Approval For Microbiota-Based Therapy
Executive Summary
If all goes well, 2020 could see the Swiss firm's Rebiotix subsidiary get a green light from the FDA for its recurrent Clostridioides difficile fecal product.
You may also be interested in...
DuPont, P&G Aim To Accelerate Probiotic Sales By Developing ‘Next Generation’ Ingredients
DuPont says it and P&G “have conducted extensive research on human commensals bacteria to help address metabolic health issues in humans.” The partnership "will help us further advance our probiotic innovation via a next generation solution that will prove beneficial to the health and well-being of consumers around the world,” says Paul Gama, P&G personal health care president.
Ferring And Blackstone Launch Gene Therapy Company
The Swiss group has decided to launch FerGene with the private equity giant to give the gene therapy nadofaragene firadenovec, which has a priority review at the FDA, a better chance for a successful launch in the US.
Ferring Leapfrogs Into Late-Stage Microbiome Race With Rebiotix Buy
The Swiss specialty drug company gains a Phase III microbiome product for the prevention of recurrent Clostridium difficile infection and a broader platform for Microbiota Restoration Therapy.
Need a specific report? 1000+ reports available
Buy Reports